Aveed’s Impact on Hematocrit Levels in Hypogonadal Males: A Two-Year Retrospective Study
Reading Time: 2 minutes Introduction Aveed, a testosterone undecanoate injection developed by Endo Pharmaceuticals, has been widely used for the treatment of hypogonadism in American males. Given the significant role of testosterone in various physiological processes, including erythropoiesis, it is crucial to monitor hematocrit levels in patients undergoing testosterone replacement therapy. This article presents a retrospective analysis of over 500 patients over a two-year period, focusing on the effects of Aveed on hematocrit levels and its implications for clinical practice. Study Design and Methodology The study involved a retrospective analysis of data collected from 520 American males diagnosed with hypogonadism and treated with Aveed...



